We’re still figuring out the side effects of GLP-1 weight-loss drugs

What happened: Research presented at an aging meeting in Boston suggests GLP-1 weight-loss drugs affect some measures of biological age. The WHO also released first guidelines on managing obesity in children and adolescents. Key numbers: Biological age two to three years younger versus Why it matters: The WHO does not recommend pharmacological treatment for children under 10, citing lack of evidence on benefits and adverse events affecting growth and development. Side effects remain under study, and Novo Nordisk and Eli Lilly face lawsuits over vision loss claims, which both dispute.

Research presented at an aging meeting in Boston suggests GLP-1 weight-loss drugs affect some measures of biological age. The WHO also released first guidelines on managing obesity in children and adolescents.

The WHO does not recommend pharmacological treatment for children under 10, citing lack of evidence on benefits and adverse events affecting growth and development. Side effects remain under study, and Novo Nordisk and Eli Lilly face lawsuits over vision loss claims, which both dispute.